The utility and practicality of the anti‐RANKL/PD‐1 BsAb strategy is illustrated not only by BsAb monotherapy activity in anti‐PD‐1‐resistant models, but also by the ability of anti‐RANKL/PD‐1 BsAb to combine with anti‐CTLA‐4 blockade, further enhancing anti‐tumor efficacy. The gene discussed is CTLA4; the disease is neoplasm.